Category CANCER

PIER MARIA FORNASARI
2019-09-11

Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer

Source https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(19)30339-X?elqTrackId=39785ec7f12f4ed79ff115249bc871f5&elq=81c0af21c850457daca48d5be457f158&elqaid=26028&elqat=1&elqCampaignId=10599 Invariant natural killer T (iNKT) cells are potent immune cells for targeting cancer; however, their clinical application has been hindered by their low numbers in cancer patients. Here, we developed a proof-of-concept for hematopoietic stem cell-engineered iNKT (HSC-iNKT) cell therapy with the potential to provide therapeutic levels of iNKT cells for a patient’s

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-09-10

T-cell therapy receives FDA’s orphan drug status for soft tissue sarcoma

The FDA has granted orphan drug designation to ADP-A2M4, an investigational specific peptide-enhanced affinity receptor T-cell therapy, for the treatment of soft tissue sarcomas. ADP-A2M4 (Adaptimmune) is an autologous, genetically modified SPEAR T-cell therapy that targets the MAGE-A4 antigen on the surface of cancer cells. Certain soft tissue sarcomas express MAGE-A4 at high levels and

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-09-06

Using MicroRNA to Starve a Tumor?

Source September 5th, 2019 by Dr. Francis Collins Tumor cells thrive by exploiting the willingness of normal cells in their neighborhood to act as accomplices. One of their sneakier stunts involves tricking the body into helping them form new blood vessels. This growth-enabling process of sprouting new blood vessels, called tumor angiogenesis, remains a vital area of

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-09-05

NIH, Cincinnati Children’s scientists develop potential strategy against leukemia drug resistance

Two-pronged approach stymies AML escape plan, could have applications to many cancers. Scientists from the National Institutes of Health and Cincinnati Children’s Hospital Medical Center have devised a potential treatment against a common type of leukemia that could have implications for many other types of cancer. The new approach takes aim at a way that

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-09-01

Immunotherapy for Pediatric Solid Tumors: What’s the Latest?

Immunotherapy can be effective in treating certain types of pediatric blood cancers, but researchers are still exploring how this type of treatment could work for pediatric solid tumors. In clinical trials, scientists are combining immunotherapy agents in an effort to jump-start the immune system against pediatric solid tumors. Source DANA-FARBER Cancer Institute New treatments that

Read More

No Comments InIMMUNOTHERAPY
PIER MARIA FORNASARI
2019-08-26

Study Reveals Key Differences Between Three Frontline Breast Cancer Drugs

Source Harvard Medical School The findings of a new Harvard Medical School study suggest important differences between three frontline drugs used to treat advanced breast cancer. The researcher’s findings were published in Cell Chemical Biology. The three CDK4/6 inhibitors, abemaciclib, palbociclib, and ribociclib have exhibited exceptional efficacy in hindering breast tumor growth, improving survival rates and prompting FDA approval.

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2019-08-23

New research published in cancer discovery identifies new drug target for glioblastoma

 A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells. While previous research has shown that a protein called

Read More

No Comments InCANCER